There’s more interest than ever in performance-based payments as they become less novel and frightening, said Jane F. Barlow, MD, MPH, MBA.
There’s more interest than ever in performance-based payments as they become less novel and frightening, said Jane F. Barlow, MD, MPH, MBA.
Transcript
Surveys by NEWDIGS show high interest by commercial payers in milestone-based contracts (MBCs), but the findings also cite barriers. Has there been any noteworthy progress in the past 12-18 months in overcoming the barriers to MBCs?
Well, yes, I would say that here has been progress. I think most notably is the progress around Medicaid best price, and the new approaches around bundled contracting and all of that that was laid out. I'm not the expert on that. But that's a removal of a significant barrier.
I work with pharmaceutical companies around market access on a day-to-day basis. And I think there's more interest than ever, around market access strategies that include performance-based payments. It might not replace rebates entirely, but as an adjunct or as a standalone. So, there's definitely more interest and more of these contracts going into play outside of gene and cell therapy, including in oncology, which we would not have talked about 3 to 5 years ago.
So, then I think momentum is building in that regard, and the barriers are being removed because people are figuring out how to do it. And it's becoming a little less novel and frightening to people who have trouble with uncertainty, and there's more adoption and interest.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More